In line with this, an analysis of the data from the PALOMA-3 clinical trial (palbociclib in combination with fulvestrant in patients with advanced ER+ BC) confirmed the important role of cyclin E during the response to CDK4/6 inhibitors. Here, CDK4 is linked to breast cancer.